| Biochemical and pharmacological characterizations of ESI-09 based EPAC inhibitors: defining the ESI-09 “therapeutic window” Y Zhu, H Chen, S Boulton, F Mei, N Ye, G Melacini, J Zhou, X Cheng Scientific reports 5 (1), 9344, 2015 | 120 | 2015 |
| A mechanism for the auto-inhibition of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel opening and its relief by cAMP M Akimoto, Z Zhang, S Boulton, R Selvaratnam, B VanSchouwen, ... Journal of Biological Chemistry 289 (32), 22205-22220, 2014 | 95 | 2014 |
| Advances in NMR methods to map allosteric sites: from models to translation S Boulton, G Melacini Chemical Reviews 116 (11), 6267-6304, 2016 | 82 | 2016 |
| A tool set to map allosteric networks through the NMR chemical shift covariance analysis S Boulton, M Akimoto, R Selvaratnam, A Bashiri, G Melacini Scientific reports 4 (1), 7306, 2014 | 76 | 2014 |
| Atomic resolution map of the soluble amyloid beta assembly toxic surfaces R Ahmed, M Akcan, A Khondker, MC Rheinstädter, JC Bozelli, RM Epand, ... Chemical science 10 (24), 6072-6082, 2019 | 56 | 2019 |
| Mechanism of selective enzyme inhibition through uncompetitive regulation of an allosteric agonist S Boulton, R Selvaratnam, JP Blondeau, F Lezoualc’h, G Melacini Journal of the American Chemical Society 140 (30), 9624-9637, 2018 | 37 | 2018 |
| Characterization of critical determinants of ACE2–SARS CoV-2 RBD interaction EEF Brown, R Rezaei, TR Jamieson, J Dave, NT Martin, R Singaravelu, ... International Journal of Molecular Sciences 22 (5), 2268, 2021 | 36 | 2021 |
| Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry T Azad, R Singaravelu, Z Taha, TR Jamieson, S Boulton, MJF Crupi, ... Molecular Therapy 29 (6), 1984-2000, 2021 | 26 | 2021 |
| SARS-CoV-2 S1 NanoBiT: A nanoluciferase complementation-based biosensor to rapidly probe SARS-CoV-2 receptor recognition T Azad, R Singaravelu, EEF Fekete, Z Taha, R Rezaei, R Arulanandam, ... Biosensors and Bioelectronics 180, 113122, 2021 | 25 | 2021 |
| Implications for SARS-CoV-2 vaccine design: Fusion of spike glycoprotein transmembrane domain to receptor-binding domain induces trimerization T Azad, R Singaravelu, MJF Crupi, T Jamieson, J Dave, EEF Brown, ... Membranes 10 (9), 215, 2020 | 25 | 2020 |
| Free energy landscape remodeling of the cardiac pacemaker channel explains the molecular basis of familial sinus bradycardia S Boulton, M Akimoto, S Akbarizadeh, G Melacini Journal of Biological Chemistry 292 (15), 6414-6428, 2017 | 24 | 2017 |
| Mechanisms of specific versus nonspecific interactions of aggregation-prone inhibitors and attenuators S Boulton, R Selvaratnam, R Ahmed, K Van, X Cheng, G Melacini Journal of medicinal chemistry 62 (10), 5063-5079, 2019 | 23 | 2019 |
| Implementation of the NMR CHEmical shift covariance analysis (CHESCA): a chemical biologist’s approach to allostery S Boulton, R Selvaratnam, R Ahmed, G Melacini Protein NMR: Methods and Protocols, 391-405, 2018 | 23 | 2018 |
| Tapping the translation potential of cAMP signalling: molecular basis for selectivity in cAMP agonism and antagonism as revealed by NMR S Boulton, M Akimoto, B VanSchouwen, K Moleschi, R Selvaratnam, ... Biochemical Society Transactions 42 (2), 302-307, 2014 | 22 | 2014 |
| Hippo signaling pathway as a central mediator of receptors tyrosine kinases (RTKs) in tumorigenesis T Azad, R Rezaei, A Surendran, R Singaravelu, S Boulton, J Dave, ... Cancers 12 (8), 2042, 2020 | 21 | 2020 |
| Recent advances in EPAC-targeted therapies: a biophysical perspective A Ahmed, S Boulton, H Shao, M Akimoto, A Natarajan, X Cheng, ... Cells 8 (11), 1462, 2019 | 20 | 2019 |
| Allosteric linkers in cAMP signalling M Akimoto, K Moleschi, S Boulton, B VanSchouwen, R Selvaratnam, ... Biochemical Society Transactions 42 (1), 139-144, 2014 | 19 | 2014 |
| Extracellular vesicles and viruses: two intertwined entities C Moulin, MJF Crupi, CS Ilkow, JC Bell, S Boulton International Journal of Molecular Sciences 24 (2), 1036, 2023 | 18 | 2023 |
| Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection S Boulton, J Poutou, NT Martin, T Azad, R Singaravelu, MJF Crupi, ... Molecular Therapy 30 (5), 1885-1896, 2022 | 18 | 2022 |
| Engineering vaccinia virus as an immunotherapeutic battleship to overcome tumor heterogeneity A Pelin, S Boulton, LA Tamming, JC Bell, R Singaravelu Expert Opinion on Biological Therapy 20 (9), 1083-1097, 2020 | 18 | 2020 |
